{"cells":[{"metadata":{},"cell_type":"markdown","source":"# WIP\n\n## Pattern matching\n### to answering \"What do we know about COVID-19 risk factors?\"\n\nThis notebook contains a pattern matching approach applied to the stated question above."},{"metadata":{"pycharm":{"is_executing":false},"trusted":true},"cell_type":"code","source":"import numpy as np\nimport pandas as pd\nimport glob\nimport os\nimport json\nfrom collections import Counter\nimport nltk\nnltk.download('punkt')\nnltk.download('stopwords')\nfrom nltk.corpus import stopwords as nltkstopwords\nfrom nltk.tokenize import word_tokenize\nimport re\nfrom gensim.parsing.preprocessing import preprocess_string, strip_tags, strip_punctuation, strip_numeric, remove_stopwords, strip_multiple_whitespaces\nfrom wordcloud import WordCloud\nimport matplotlib.pyplot as plt","execution_count":123,"outputs":[{"output_type":"stream","text":"[nltk_data] Downloading package punkt to /usr/share/nltk_data...\n[nltk_data]   Package punkt is already up-to-date!\n[nltk_data] Downloading package stopwords to /usr/share/nltk_data...\n[nltk_data]   Package stopwords is already up-to-date!\n","name":"stdout"}]},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"base_path = \"../input/CORD-19-research-challenge\"\n\nbiorxiv_medrxiv = \"biorxiv_medrxiv/biorxiv_medrxiv/pdf_json\"\ncomm_use_subset = \"comm_use_subset/comm_use_subset/pdf_json\"\nnoncomm_use_subset = \"noncomm_use_subset/noncomm_use_subset/pdf_json\"\ncustom_license = \"custom_license/custom_license/pdf_json\"","execution_count":124,"outputs":[]},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"files = []\n\ndef read_files(directory):\n    files_in_dir = [f for f in glob.glob(os.path.join(base_path, directory) + \"/*.json\", recursive=True)]\n    files.extend(files_in_dir)\n    raw_body_texts_of_file = []\n    for f in files_in_dir:\n        data = json.load(open(f))\n        #for key in data.keys():\n        #    print(\"{}: {}\\n\".format(key, data[key]))\n        \n        body_text = \"\"\n        for i in range(len(data[\"body_text\"])):\n            body_text += \" \" + data[\"body_text\"][i][\"text\"]\n        \n        body_text = re.sub(' +', ' ', body_text)\n        raw_body_texts_of_file.append(body_text)\n    return raw_body_texts_of_file\n\nraw_body_texts = []\nraw_body_texts.extend(read_files(biorxiv_medrxiv))\nraw_body_texts.extend(read_files(comm_use_subset))\n#raw_body_texts.extend(read_files(noncomm_use_subset))\n#raw_body_texts.extend(read_files(custom_license))","execution_count":125,"outputs":[]},{"metadata":{"pycharm":{"is_executing":false},"trusted":true},"cell_type":"code","source":"def print_title(idx):\n    print(json.load(open(files[idx]))[\"metadata\"][\"title\"])\n\ndef print_text(filenumber, start_idx, end_idx):\n    text = raw_body_texts[filenumber]\n    start_idx = max(0, start_idx)\n    end_idx = min(len(text), end_idx)\n    print(text[start_idx:end_idx])\n    \ndef print_body_text(filenumber):\n    data = json.load(open(files[filenumber]))\n    body_text = \"\"\n    for i in range(len(data[\"body_text\"])):\n        body_text += \" \" + data[\"body_text\"][i][\"text\"]\n    body_text = re.sub(' +', ' ', body_text)\n    print(body_text)","execution_count":126,"outputs":[]},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"print(\"Found {} raw body texts\".format(len(raw_body_texts)))","execution_count":127,"outputs":[{"output_type":"stream","text":"Found 10707 raw body texts\n","name":"stdout"}]},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"NUMBER_OF_FILES = len(raw_body_texts)\nWINDOW_SIZE = 200","execution_count":128,"outputs":[]},{"metadata":{},"cell_type":"markdown","source":"### Search papers by regex patterns\nThe regex patterns contain on one hand words which might appear in context of risk factors and on the other hand some risk factors."},{"metadata":{"trusted":true},"cell_type":"code","source":"factor___risk_pattern = r\"(factor(.){0,9}risk)\" # for example for \"factors of risk\"\nrisk_factor_pattern = r\"(risk(.){0,4}factor)\" # for example risk factors\nrisk_pattern = r\"(risk)\"\nhigh_risk_pattern = r\"(high(.){0,6}risk)\"\ncomorbdit_pattern = r\"(comorbdit)\"\nco_infects_pattern = r\"(co(.){0,4}infect)\"\nneonat_pattern = r\"(neonat)\"\npregnant_pattern = r\"(pregnant)\"\nsmoking_pattern = r\"(smoking)\"\ncancer_pattern = r\"(cancer)\"\naverse_outcomes_pattern = r\"(advers(.){0,4}outcome)\"\n\nPATTERNS = [\n    factor___risk_pattern,\n    risk_factor_pattern,\n    #risk_pattern,\n    high_risk_pattern,\n    #comorbdit_pattern,\n    #co_infects_pattern,\n    #neonat_pattern,\n    #pregnant_pattern,\n    #smoking_pattern,\n    #cancer_pattern,\n    averse_outcomes_pattern\n]\n\nCUSTOM_FILTERS = [lambda x: x.lower(), strip_tags, strip_punctuation]\nCUSTOM_FILTERS_EXCLUDE_NUMERIC = [lambda x: x.lower(), strip_tags, strip_punctuation, strip_numeric]","execution_count":129,"outputs":[]},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"%%time\ndef extract_windows_containing(pattern, print_out=True):\n    indices = []\n    preprocessed_texts = []\n    for idx in range(NUMBER_OF_FILES):\n        filtered_sentence = raw_body_texts[idx]\n        preprocessed_texts.append(filtered_sentence)\n        \n        indices_of_file = [(m.start(0), m.end(0)) for m in re.finditer(pattern, filtered_sentence)]\n        indices.append(indices_of_file)\n    \n    return indices, preprocessed_texts\n\n\nindices = [[] for _ in range(NUMBER_OF_FILES)]\nfor pattern in PATTERNS:\n    indices_, preprocessed_texts = extract_windows_containing(pattern)\n    for i in range(len(indices_)):\n        indices[i].extend(indices_[i])\n\nprint(\"Found {} candidates\".format(len([1 for a in indices if len(a)!=0])))","execution_count":130,"outputs":[{"output_type":"stream","text":"Found 2160 candidates\nCPU times: user 2.77 s, sys: 1.13 ms, total: 2.77 s\nWall time: 2.78 s\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"Tokenize and remove stopwords"},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"%%time\ndef process_file(file_number, indices_of_file, filters):\n    tokenized_matches = []\n    for match in indices_of_file:\n        start = match[0]-WINDOW_SIZE\n        end = match[1]+WINDOW_SIZE\n        text = preprocessed_texts[file_number][start:end]\n        tokenized = preprocess_string(text, filters)\n        tokenized_matches.append(tokenized)\n\n    return tokenized_matches\n\ntokenized_data = []\nfor file_number, indices_of_file in enumerate(indices):\n    if len(indices_of_file) != 0:\n        for data in process_file(file_number, indices_of_file, CUSTOM_FILTERS_EXCLUDE_NUMERIC):\n            for word in data:\n                if len(word) > 2:\n                    tokenized_data.append(word)\n\nnltk_stop_words = set(nltkstopwords.words('english'))\nfor word in [\"high\", \"risk\", \"factor\", \"patients\", \"factors\", \"disease\"]:\n    nltk_stop_words.add(word)\nwithout_stopwords = [word for word in tokenized_data if word not in nltk_stop_words]\nprint(\"Number of words without stopwords: {}\\n with stopwords {}\".format(len(without_stopwords), len(tokenized_data)), end=\"\\n\\n\")","execution_count":131,"outputs":[{"output_type":"stream","text":"Number of words without stopwords: 236676\n with stopwords 351442\n\nCPU times: user 964 ms, sys: 3.69 ms, total: 968 ms\nWall time: 969 ms\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"#### Show words by count i.e. words which often appear in our current results\n\nWe can see some potential risk factors like  ('asthma', 2148) which means asthma appeared 2148 times in the context of potential words which indicates that a passage is about risk factors.\nHowever just looking at context words is not so useful, but we can use it as an intermediate step to further look at potential risk factors indentfied here."},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"counts = Counter(without_stopwords)\nprint(counts.most_common(500))","execution_count":145,"outputs":[{"output_type":"stream","text":"[('infection', 1914), ('study', 1721), ('higher', 1332), ('associated', 1269), ('may', 1149), ('age', 1071), ('also', 1066), ('studies', 1047), ('influenza', 947), ('severe', 905), ('data', 844), ('cases', 820), ('health', 791), ('transmission', 772), ('virus', 762), ('analysis', 731), ('population', 730), ('infections', 722), ('mortality', 705), ('respiratory', 697), ('among', 690), ('children', 666), ('low', 661), ('however', 647), ('clinical', 609), ('group', 608), ('reported', 597), ('identified', 590), ('one', 579), ('used', 560), ('years', 552), ('significant', 545), ('individuals', 545), ('viral', 536), ('diseases', 536), ('results', 523), ('could', 523), ('potential', 521), ('found', 518), ('human', 515), ('control', 512), ('groups', 511), ('table', 510), ('viruses', 497), ('exposure', 496), ('countries', 493), ('important', 485), ('infected', 483), ('case', 479), ('including', 478), ('number', 477), ('two', 475), ('treatment', 474), ('use', 473), ('model', 467), ('hospital', 458), ('based', 447), ('increased', 439), ('mers', 439), ('using', 423), ('compared', 413), ('care', 413), ('areas', 412), ('cov', 409), ('well', 408), ('rsv', 408), ('related', 406), ('non', 398), ('covid', 396), ('due', 395), ('contact', 389), ('prevalence', 389), ('pneumonia', 386), ('death', 384), ('identify', 382), ('time', 374), ('outcomes', 371), ('different', 365), ('first', 363), ('vaccination', 363), ('severity', 357), ('asthma', 357), ('included', 349), ('people', 346), ('within', 343), ('patient', 343), ('level', 339), ('sars', 338), ('development', 337), ('specific', 333), ('likely', 332), ('early', 332), ('therefore', 332), ('previous', 331), ('chronic', 331), ('lower', 325), ('incidence', 322), ('significantly', 321), ('considered', 320), ('association', 320), ('hpv', 318), ('highest', 317), ('rate', 316), ('outcome', 315), ('although', 312), ('populations', 310), ('known', 310), ('infectious', 309), ('surveillance', 309), ('showed', 305), ('independent', 294), ('shown', 294), ('symptoms', 289), ('common', 286), ('public', 282), ('vaccine', 282), ('three', 281), ('would', 280), ('pandemic', 280), ('cancer', 278), ('hiv', 277), ('medical', 276), ('outbreak', 275), ('major', 275), ('positive', 274), ('information', 273), ('levels', 269), ('several', 267), ('illness', 266), ('adverse', 265), ('observed', 264), ('infants', 262), ('addition', 261), ('conditions', 261), ('china', 261), ('might', 260), ('models', 259), ('acute', 259), ('present', 257), ('period', 257), ('regression', 257), ('without', 253), ('many', 251), ('available', 250), ('days', 249), ('developing', 249), ('prevention', 248), ('possible', 248), ('blood', 246), ('thus', 246), ('year', 245), ('presence', 245), ('test', 243), ('figure', 243), ('variables', 243), ('status', 241), ('host', 240), ('measures', 240), ('less', 238), ('evidence', 237), ('admission', 237), ('icu', 237), ('workers', 235), ('findings', 234), ('new', 233), ('history', 223), ('spread', 222), ('pathogens', 222), ('older', 220), ('confirmed', 219), ('similar', 219), ('diabetes', 216), ('increase', 216), ('knowledge', 215), ('include', 214), ('screening', 213), ('outbreaks', 212), ('need', 209), ('score', 209), ('role', 206), ('cohort', 205), ('large', 205), ('even', 204), ('especially', 204), ('cell', 203), ('performed', 202), ('women', 202), ('cause', 201), ('cats', 201), ('adults', 200), ('sex', 199), ('fig', 198), ('recent', 198), ('response', 198), ('animal', 197), ('type', 197), ('effect', 195), ('individual', 195), ('logistic', 193), ('immune', 193), ('system', 192), ('research', 192), ('effective', 191), ('months', 191), ('general', 188), ('result', 188), ('whether', 186), ('underlying', 186), ('cells', 185), ('diagnosis', 185), ('detection', 185), ('epidemiological', 185), ('following', 184), ('contacts', 183), ('humans', 183), ('animals', 183), ('since', 182), ('environmental', 182), ('primary', 181), ('rates', 180), ('particularly', 180), ('burden', 179), ('reduce', 179), ('day', 179), ('hospitalization', 179), ('effects', 179), ('lung', 176), ('types', 176), ('healthcare', 174), ('work', 174), ('poultry', 174), ('determine', 172), ('onset', 171), ('conducted', 171), ('limited', 169), ('elderly', 168), ('provide', 168), ('close', 166), ('risks', 166), ('analyses', 165), ('pathogen', 165), ('impact', 165), ('total', 164), ('according', 164), ('community', 164), ('complications', 162), ('multiple', 162), ('spatial', 162), ('multivariate', 161), ('current', 161), ('given', 160), ('therapy', 160), ('fever', 160), ('example', 159), ('estimated', 159), ('assess', 159), ('young', 159), ('characteristics', 158), ('regions', 158), ('genetic', 158), ('four', 157), ('respectively', 157), ('old', 157), ('hcws', 157), ('area', 157), ('distribution', 156), ('suggest', 155), ('additional', 154), ('value', 153), ('epidemic', 153), ('methods', 153), ('poor', 153), ('small', 153), ('single', 152), ('aged', 152), ('differences', 150), ('strategies', 149), ('species', 149), ('review', 148), ('another', 147), ('moreover', 147), ('aki', 146), ('overall', 144), ('occurrence', 144), ('progression', 143), ('least', 143), ('samples', 143), ('male', 142), ('defined', 142), ('size', 142), ('smoking', 142), ('sample', 142), ('highly', 141), ('increasing', 141), ('protective', 141), ('social', 141), ('laboratory', 140), ('demonstrated', 140), ('main', 140), ('relative', 140), ('better', 139), ('region', 139), ('proportion', 138), ('odds', 138), ('seasonal', 138), ('failure', 137), ('zoonotic', 137), ('suggested', 136), ('indicated', 136), ('hospitalized', 136), ('prevent', 135), ('probability', 135), ('vaccines', 135), ('strains', 135), ('subjects', 134), ('detected', 134), ('developed', 134), ('index', 134), ('global', 133), ('bacterial', 133), ('evaluate', 133), ('management', 133), ('life', 133), ('described', 133), ('approach', 133), ('felv', 133), ('lack', 132), ('travel', 132), ('collected', 132), ('pregnant', 132), ('long', 131), ('assessment', 131), ('critical', 130), ('deaths', 130), ('bias', 130), ('country', 130), ('sari', 130), ('preprint', 128), ('identification', 128), ('south', 128), ('participants', 127), ('needed', 126), ('mean', 126), ('caused', 126), ('heart', 125), ('direct', 125), ('targeted', 125), ('prior', 125), ('still', 124), ('local', 124), ('family', 124), ('understanding', 123), ('international', 122), ('often', 122), ('interventions', 122), ('per', 122), ('various', 122), ('furthermore', 121), ('ratio', 121), ('associations', 121), ('secondary', 121), ('negative', 121), ('statistical', 120), ('pre', 120), ('function', 120), ('order', 120), ('previously', 120), ('help', 119), ('cities', 119), ('testing', 118), ('lead', 118), ('future', 118), ('report', 117), ('morbidity', 117), ('greater', 117), ('ards', 117), ('develop', 116), ('adult', 116), ('birth', 116), ('fiv', 116), ('second', 115), ('recommended', 115), ('household', 115), ('isolation', 114), ('adjusted', 114), ('quality', 114), ('relatively', 114), ('introduction', 114), ('drug', 113), ('range', 113), ('protein', 113), ('patterns', 113), ('density', 113), ('farms', 113), ('hospitals', 112), ('across', 112), ('comorbidities', 112), ('syndrome', 112), ('living', 112), ('estimate', 111), ('gender', 111), ('show', 111), ('exposed', 111), ('herd', 110), ('ill', 110), ('consistent', 110), ('causes', 110), ('healthy', 110), ('importance', 110), ('province', 109), ('world', 109), ('times', 109), ('obesity', 109), ('reports', 108), ('protection', 108), ('settings', 108), ('dengue', 108), ('support', 107), ('changes', 107), ('conclusion', 107), ('cmv', 107), ('evaluated', 106), ('pregnancy', 106), ('regarding', 106), ('stay', 105), ('values', 105), ('identifying', 105), ('particular', 105), ('established', 105), ('hypertension', 104), ('injury', 104), ('potentially', 104), ('currently', 104), ('certain', 104), ('term', 103), ('selected', 103), ('cardiovascular', 103), ('antiviral', 103), ('activity', 103), ('sepsis', 103), ('vaccinated', 103), ('appropriate', 102), ('susceptible', 102), ('younger', 102), ('investigated', 102), ('events', 102), ('presented', 101), ('count', 101), ('five', 101), ('others', 101), ('relationship', 100), ('criteria', 100), ('whereas', 100), ('responses', 100), ('key', 100), ('target', 100), ('like', 99), ('pulmonary', 99), ('either', 99), ('novel', 99), ('food', 99), ('systems', 98), ('susceptibility', 98), ('difference', 97), ('correlation', 97), ('leading', 97), ('preventive', 97), ('national', 97), ('practices', 96), ('made', 96), ('maternal', 96), ('frequently', 96), ('emerging', 96), ('survival', 95), ('expression', 95), ('persons', 95), ('air', 95), ('intensive', 95), ('gene', 95), ('procedures', 94), ('assessed', 94), ('aim', 94), ('members', 93), ('antibody', 93), ('tract', 93), ('moderate', 93), ('likelihood', 93), ('variable', 93), ('income', 93), ('majority', 92), ('tested', 92), ('required', 92), ('suggests', 91), ('method', 91), ('occur', 91), ('frequency', 91), ('staff', 90), ('intervention', 90), ('elevated', 90), ('literature', 90)]\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"Visualization of the top words in a word cloud"},{"metadata":{"trusted":true},"cell_type":"code","source":"text = \" \".join(without_stopwords)\nwordcloud = WordCloud(max_font_size=50, max_words=100, background_color=\"white\").generate(text)\n\nplt.imshow(wordcloud, interpolation='bilinear')\nplt.axis(\"off\")\nplt.show()","execution_count":133,"outputs":[{"output_type":"display_data","data":{"text/plain":"<Figure size 432x288 with 1 Axes>","image/png":"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\n"},"metadata":{"needs_background":"light"}}]},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"}},"cell_type":"markdown","source":"#### Search potential passages for given potential risks\n\nNow we are going through the preprocessed data and look for possible risks, which we collected through our knowledge and the experiment above.\n\nWe print the file number, the index where the inital match of the experiment above happens and an extract of the body text.\n\nBecause some patterns might match for the same window/extract of text we adjust the index to contain a bigger window to avoid intersecting text windows."},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"POTENTIAL_RISKS = [\n    \"smoking\",\n    \"pulmonary diseas\", \n    \"elder\",\n    \"diabetes\",\n    \"old\",\n    \"age\",\n    \"cancer\", \n    \"cardiac\",\n    \"cardio\"]","execution_count":134,"outputs":[]},{"metadata":{"pycharm":{"is_executing":false,"name":"#%%\n"},"trusted":true},"cell_type":"code","source":"def doit(only_directly_related_files=False):\n    print_counter = 0\n    overall_processed_indices_count = 0\n    for file_number, indices_of_file in enumerate(indices):\n        if only_directly_related_files and file_number in not_directly_related_files:\n            continue\n        if len(indices_of_file) != 0:\n            matches = process_file(file_number, indices_of_file, CUSTOM_FILTERS)\n            processed_indices_of_file = []\n            indices_of_file = sorted(indices_of_file)\n            # adjust indices\n            for i in range(len(indices_of_file)):\n                if i != 0 and len(processed_indices_of_file) != 0:\n                    if abs(processed_indices_of_file[-1][0] - indices_of_file[i][0]) > 100 and abs(processed_indices_of_file[-1][1] - indices_of_file[i][1]) > 100:\n                        processed_indices_of_file.append(indices_of_file[i])\n                    else:\n                        min_ = min(indices_of_file[i][0], processed_indices_of_file[-1][0])\n                        max_ = max(indices_of_file[i][1], processed_indices_of_file[-1][1])\n                        del processed_indices_of_file[-1]\n                        processed_indices_of_file.append((min_, max_))\n                else:\n                    processed_indices_of_file.append(indices_of_file[i])\n            overall_processed_indices_count += len(processed_indices_of_file)\n\n            for index, match in zip(processed_indices_of_file, matches):\n                for pattern in POTENTIAL_RISKS:\n                    if pattern in match:\n                        windows_size = max(int(len(\" \".join(match))/2), 300)\n                        if print_counter < 50:\n                            print(\"File number: {} index pair: {}\".format(file_number, index))\n                            print_text(file_number, index[0]-windows_size, index[1]+windows_size)\n                            print(\"\\n\\n\")\n                            print_counter += 1\n                        break\n    return overall_processed_indices_count\n\noverall_processed_indices_count = doit()","execution_count":135,"outputs":[{"output_type":"stream","text":"File number: 12 index pair: (3896, 3907)\ncal authority, is essential 245 for emergency management. outbreak control. The study also found that uptake of prevention practices was poorer among older 247 members of the public, which warrants serious attention. It has been found that older 248 adults affected by 2019-nCoV are likely to have a higher risk of complications and 249 mortality (4). There is a need to find out whether a lack of appropriate prevention 250 practices among people of older age is due to knowledge deficiency or to their being 251 out-of-reach of current public health intervention. The finding that nearly 15% of people would b\n\n\n\nFile number: 15 index pair: (7902, 7918)\ns associated with inferior outcome 6 . Interestingly, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Given that Case 2 has a history of long-term use of glucocorticoids, which is the high-risk factor for severe infection and progression, overall, the severity of Case 2 was much optimistic than average status in her age group, since it was reported elder people infected SARS-CoV-2 have much worse prognosis 10 . Furthermore, though his another relative also got fever at the time of visit, the vir\n\n\n\nFile number: 30 index pair: (3731, 3742)\n . Further, a \"medical comorbidity burden' index score was computed from the medical history taken during the routine interview all participants completed during data collection. Participants were assigned a '1' if they endorsed a history of each of the following medical conditions: cerebrovascular risk factors including hypertension, heart failure, COPD, anemia, diabetes; endocrine dysfunction including thyroid disease, testosterone therapy, estrogen therapy; kidney disease. Participants were assigned a '0' for all medical conditions they did not endorse. The copyright holder for this preprint (which wa\n\n\n\nFile number: 30 index pair: (9816, 9827)\nhy aging cohort to reliably predict participant age based on metrics of WM microstructure, we found that the brain WM age difference (BAG) was significantly higher in our HIV+ group than in the highly comparable HIV-group. Further, BAG widened with increasing age, suggesting that advancing age is a risk factor for neurodegeneration. Additionally, larger BAG was associated with worse cognitive performance, indicating that this . CC-BY-NC-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.\n\n\n\nFile number: 71 index pair: (7439, 7450)\n be older with higher levels of cardiac injury markers and higher levels of systematic inflammation markers. Patients with higher NT-proBNP (above 88.64 pg/mL) level had lower cumulative survival rate. After adjusting for potential cofounders in separate modes, NT-proBNP presented as an independent risk factor of in-hospital death in patients with severe COVID-19. All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1\n\n\n\nFile number: 96 index pair: (29601, 29677)\n, but the curve will also be broader. Some containment strategies could even be counterproductive in other ways. For instance, the simple model used in Fig 12 does not account for age-stratification. In diseases such as COVID-19, where children develop mostly mild forms, while elderly people have a high risk of dying. (Zimmermann Curtis 2020) Hence, containment of high-risk groups, like elderly people in nursing homes (see the Washington State example) is highly effective in protecting them from becoming infected and reducing the pool that would have to reach herd immunity. A substantial increase in the duration of the epidemic, however, might make effective containme\n\n\n\nFile number: 96 index pair: (31225, 31234)\nrictions are discussed to be lifted on 04-12 (day 100). The model predicts that such an intervention would reduce the number of deaths in New York and Detroit (and possibly some other parts of the U.S., but the virus would linger on for another two months, so that it would not be safe for (elderly) high-risk people to participate in this year's Easter activities. Until a vaccine will become available, the only pharmacological strategy to reduce the number of deaths is to reduce the damage the infection (and immune system) does, e.g., by reducing the initial viral load, (Chu 2004) and making sure that p\n\n\n\nFile number: 102 index pair: (8205, 8214)\nnation for this is that the prevalence of malignancy was higher in males. Liang et al. [19] found that in severe COVID-19 patients, those with cancer had poorer outcomes from COVID-19. In addition, more men in our study were co-infected with bacteria or influenza virus, which may somewhat result in high risk. Rothberg et al. [20] reported that bacterial infection was a common pulmonary complication of influenza. We found that positive influenza A antibody were detected in 5 men patients but not in women. Otherwise a higher rate of increased procalcitonin was also observed in men. These findings suggest\n\n\n\nFile number: 105 index pair: (14631, 14642)\ny to be older, male, with temperature over 38.5 o C, symptom of dyspnoea, underlying cardiovascular disease, and longer waiting period from onset of symptom to hospital admission, compared to those not admitted to the ICU. This suggests that age, sex, high fever, admission time and co-morbidity are risk factors for disease severity. Compared with non-ICU patients, patients who received ICU care had numerous laboratory abnormalities. These abnormalities suggest that SARS-Cov-2 infection can be associated with cellular immune deficiency, coagulation activation, myocardial injury, hepatic injury and kidney \n\n\n\nFile number: 105 index pair: (17248, 17259)\nical manifestations occur, including a spectrum form T cell deficiency to symptoms of digestive system involvement. Older age, male, fever over 38.5 o C, symptom of dyspnoea, the presence of underlying cardiovascular disease, and longer waiting period from onset of symptom to hospital admission are risk factors associated with the severity of disease. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.0\n\n\n\nFile number: 106 index pair: (11096, 11107)\nof studies have shown that diabetic patients had higher mortality and morbidity of severe medical illness, such as myocardial infarction, and high FBG plays an independent predictive role in hospitalized non-diabetic patients as well [17, 18, 19] . Diabetes has also been identified as a significant risk factor for severe disease following respiratory tract infections [20] . Several studies demonstrated that diabetes was associated with increased the risks of severity and mortality after SARS-CoV and MERS-CoV . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has grant\n\n\n\nFile number: 112 index pair: (1468, 1479)\nes in mainland China, including 3,267 deaths. Internationally, a total of 288,275 confirmed cases have been reported from 186 countries outside of, including 9,517 deaths. Considering the global public health threat posed by COVID- 19 , unraveling the prognostic factors for patients, especially the risk factors of mortality associated with COVID-19, has important implications for clinical practice and is urgently warranted. Studies have indicated that severe cases tend to be older in age [6] [8] and are more likely to have had pre-existing medical conditions, including but not limited to hypertension [3]\n\n\n\nFile number: 112 index pair: (6655, 6666)\nd to rule out the multicollinearity concern before fitting any model. Univariate weighted Cox models were performed for each of the comorbidity of interest. Multivariate weighted Cox model was used to determine if pre-existing comorbidity yielded prognostic hazard information. Other than the common risk factors (age, gender and history of surgery), the multivariate model also adjusted for location of diagnosis (in vs. outside of Hubei Province) and early period of pandemic (after vs. before January 11 th , 2020 when no-intervention was taken by the government) [20] . Although matching was based on age an\n\n\n\nFile number: 112 index pair: (13040, 13051)\ndeath risk of COVID-19: one additional pre-existing comorbidity led to an estimated 29% increase of death risk (p=0.01). However, after adjusting for confounders, CHD was the only significant risk factor for COVID-19 mortality after adjusting for confounders. Patients with CHD had 92% significantly higher risk of mortality in COVID-19, compared to patients without CHD (p=0.009). The estimated median survival times for those with CHD was 13 days (95% CI: 11-23 days), at lease 67 days shorter than those without CHD (p<0.001). Moreover, we estimated that COVID-19 patients with hypertension had 43% higher de\n\n\n\nFile number: 138 index pair: (13368, 13377)\nh the increase of newly confirmed and severe cases, the management of severe patients brings huge challenge in efficiently controlling the COVID-19 outbreak. Some patients progressed rapidly with ARDS and subsequent multiple organ dysfunction syndrome (MODS). 2 Early identification of patients with high risk to develop ARDS or MODS and risk stratification management might be helpful to reduce mortality. In our cohort, the prevalence of severe NCP was 10.6%, which was . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the prep\n\n\n\nFile number: 138 index pair: (19653, 19664)\nng hospitalization were not included in the analysis. More comprehensive investigation of the relationship between CT characteristics and cytokine storm induced by COVID-2019 needs to be performed. In conclusion, our results showed that higher NLR and CT severity score on admission were independent risk factors for short-term progression in patients with NCP. The CT findings in patients with NCP were associated with inflammatory levels and both them have the potential to predict disease progression. Imported and nonimported patients outside Wuhan should be managed equally, and early admission is required\n\n\n\nFile number: 141 index pair: (17051, 17060)\nt patterns could contribute to different attack rates by age group, but we include age-specific contact patterns in the model. Second, we assume that, as a result of more severe symptoms at older ages, all cases in symptomatic individuals aged 80 years were reported. We cannot confirm this, but the high risk of death from Covid-19 amongst the elderly was reported very early on [3] , so we believe that most old people with symptoms sought care. If this assumption is wrong, mortality in our study would be overestimated. Sensitivity analyses show a linear relation between the ascertainment proportion for \n\n\n\nFile number: 159 index pair: (7756, 7767)\nrare. Chest computed tomography scan showing ground glass opacity of diagnosed patients account for 63.3%, whereas the severe pneumonia up to 76.2%, these were inconsistent with other studies 12 data suggested that gender may not be an influence factor in 2019-nCov infection, yet advanced age was a risk factor for viral infection and poor prognosis. Our data of laboratory detection indicated that the white blood cells and C-reactive protein level were elevated in severe case series and the lymphocytes were decreased. The results suggested that severe pneumonia may be accompanying bacterial infection and \n\n\n\nFile number: 159 index pair: (8350, 8361)\nal infection and immune deficiency may be also a risk factor for unfavourable prognosis in patients 13 . In addition, alanine transaminase (ALT), aspartate transaminase (AST) and creatinine (CR) were elevated in the patients of severe pneumonia. The results suggested that 2019-nCov may be carries a risk factor of impaired liver and kidney function. In summary, our data provide more information that advanced age, lower lymphocytes levels at the diagnosed COVID-19 patients may be a risk factor for unfavourable prognosis. The white blood cells and C-reactive protein level elevated in severe COVID-19 patient\n\n\n\nFile number: 159 index pair: (8535, 8546)\nnine (CR) were elevated in the patients of severe pneumonia. The results suggested that 2019-nCov may be carries a risk factor of impaired liver and kidney function. In summary, our data provide more information that advanced age, lower lymphocytes levels at the diagnosed COVID-19 patients may be a risk factor for unfavourable prognosis. The white blood cells and C-reactive protein level elevated in severe COVID-19 patients may be accompanying bacterial infection. 2019-nCov may be carries a risk factor of impaired liver and kidney function. . CC-BY-NC-ND 4.0 International license It is made available und\n\n\n\nFile number: 211 index pair: (6976, 6987)\nbetween survivors and non-survivors. Non-survivors showed significantly higher white blood cell and neutrophil count, NLR, SII, CRP, procalcitonin, and D-dimer, and lower red blood cell, lymphocyte, and platelet count compared to survivors (Table 1) . The independent predictors were identified from risk factors relating to adverse clinical outcome by logistic regression model. As indicated in table 2, age, neutrophil count, platelet count, and CRP were found to be independent predictors of adverse outcome. Hosmer and Lemeshow test showed a good model adequacy ( 2 =6.64, p=0.576). To determine and compar\n\n\n\nFile number: 211 index pair: (7171, 7186)\nte, and platelet count compared to survivors (Table 1) . The independent predictors were identified from risk factors relating to adverse clinical outcome by logistic regression model. As indicated in table 2, age, neutrophil count, platelet count, and CRP were found to be independent predictors of adverse outcome. Hosmer and Lemeshow test showed a good model adequacy ( 2 =6.64, p=0.576). To determine and compare the accuracy of these factors in adverse outcome prediction, ROC curve analysis was performed and the difference in AUCs was tested. Figure 1 ). The AUC of CRP was significantly higher than that of\n\n\n\nFile number: 211 index pair: (7322, 7337)\nome by logistic regression model. As indicated in table 2, age, neutrophil count, platelet count, and CRP were found to be independent predictors of adverse outcome. Hosmer and Lemeshow test showed a good model adequacy ( 2 =6.64, p=0.576). To determine and compare the accuracy of these factors in adverse outcome prediction, ROC curve analysis was performed and the difference in AUCs was tested. Figure 1 ). The AUC of CRP was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z = 2.09, p =0.028), and platelet count (z = 5.65, p <0.001) for adverse outcome prediction. With a cut-off .\n\n\n\nFile number: 211 index pair: (7593, 7608)\naccuracy of these factors in adverse outcome prediction, ROC curve analysis was performed and the difference in AUCs was tested. Figure 1 ). The AUC of CRP was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z = 2.09, p =0.028), and platelet count (z = 5.65, p <0.001) for adverse outcome prediction. With a cut-off . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint CC-BY-NC-ND 4.0 International license I\n\n\n\nFile number: 211 index pair: (9731, 9746)\nbout the prognostic value of CRP in patients with COVID-19. The pathological mechanism of COVID-19 has not been fully uncovered. In this study, the median age of non-survivors was 71 (64-80) years, significantly higher than 57 (40-69) years in survivors. Further, age was an independent predictor of adverse outcome and discriminator of severe/critical illness, which suggested that old people are more vulnerable to SARS-CoV-2 and more likely to develop severe/critical disease. 5, 6, 8 Elevated neutrophil count was observed in patients with severe illness compared to those with non-severe illness. 7 In this stu\n\n\n\nFile number: 211 index pair: (16327, 16342)\ndisplay the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.21.20040360 doi: medRxiv preprint 2 0 Receiver operating characteristic (ROC) curves of age, neutrophil count, platelet count, and C-reactive protein for adverse outcome prediction. The area under the curve (AUC) of age, neutrophil count, platelet count, and C-reactive protein for predicting adverse outcome was 0.833, 0.820, 0.678, and 0.896, respectively. The AUC of C-reactive protein was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z\n\n\n\nFile number: 211 index pair: (16466, 16481)\n020.03.21.20040360 doi: medRxiv preprint 2 0 Receiver operating characteristic (ROC) curves of age, neutrophil count, platelet count, and C-reactive protein for adverse outcome prediction. The area under the curve (AUC) of age, neutrophil count, platelet count, and C-reactive protein for predicting adverse outcome was 0.833, 0.820, 0.678, and 0.896, respectively. The AUC of C-reactive protein was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z = 2.09, p =0.028), and platelet count (z = 5.65, p <0.001) for adverse outcome prediction. . CC-BY-NC-ND 4.0 International license It is m\n\n\n\nFile number: 211 index pair: (16706, 16721)\nount, platelet count, and C-reactive protein for predicting adverse outcome was 0.833, 0.820, 0.678, and 0.896, respectively. The AUC of C-reactive protein was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z = 2.09, p =0.028), and platelet count (z = 5.65, p <0.001) for adverse outcome prediction. . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.21.20040360 doi: med\n\n\n\nFile number: 228 index pair: (691, 706)\nnable to appropriately respond to increased cardiorespiratory demands 43 of surgery due to reduced cardiorespiratory reserve. [1, 2] The CPET-derived measure of anaerobic 44 threshold (AT) of <11 ml.min -1 kg -1 has been identified in multiple studies and systematic reviews to 45 be associated with adverse outcomes, mortality, and longer lengths of stay in a variety of surgeries, 46 including intra-abdominal and intra-thoracic procedures. [2] [3] [4] The AT represents the point where ATP generation cannot be met by mitochondrial metabolism. It is considered a good measure as it reflects 48 oxygen delivery an\n\n\n\nFile number: 228 index pair: (2753, 2764)\nosure [23] or pre-operative [1] [2] [3] [4] 10] The CPET-evaluated total oxygen consumption at peak exercise (peak VO2) has also been used for high We concluded that assuming the study had sufficient power, neither age, nor more surprisingly SpO2 as Other measurements that were associated with the higher risk status were higher serum bicarbonate and We used the derived relationship between and AT and VSAQ to model the expected cut off by age on 231 the VSAQ that might indicate an individual in a lower risk category based on the established AT of 11 232 ml.min -1 .kg -1 . As noted in Figure 4 , this diff\n\n\n\nFile number: 228 index pair: (3504, 3515)\nranted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is suggestive of lower risk irrespective of age, whereas older individuals in the \"best\" New York Heart 234 Association (NYHA) category [25] could still fall into the higher risk category defined by AT 235 <11ml.min -1 .kg -1 . In younger individuals, lower risk would be assigned even in the setting of more 236 limited exercise capacity, (VSAQ 4-7, NYHA II). In other words, the VSAQ provided sufficient 237 granularity to indicate where age-related physiology would be 'offse\n\n\n\nFile number: 243 index pair: (12211, 12222)\neatment of adenovirus pneumonia 42 . While other studies revealed that CRRT was a risk factor for mortality in patients with MERS-CoV 16 Although CRRT treatment improved patient survival, 54.5% of patients with CRRT treatment died during our follow-up. In patients with CRRT, we further explored the risk factors for death for better management and treatment. We derived that older age, and higher levels of IL-1, IL-2 receptor, hs-cTnI, and NT-proBNP were independently associated with a higher allcause mortality in patients with CRRT. IL-1 is known as a lymphocyte-stimulating factor, produced by activated\n\n\n\nFile number: 263 index pair: (374, 458)\ns outbreak has quickly became a global public health issue, with a total of 168,019 infected, 6,610 deaths and 148 countries affected as of Mar 16, 2020 (World Health Organization, WHO 1 ). One of main challenges facing its medical care is the lack of effective tools for selecting patients posing a high risk of mortality at an early stage. Previous studies have explored risk factors associated with severity levels of the pneumonia. For example, Zhou et.al 2 identified that the older age and a high level of D-dimer are associated with in-hospital death, while Shi et.al 3 found that the manifestation of chest CT imaging abnormalities correlates with disease states. However, the\n\n\n\nFile number: 263 index pair: (6651, 6660)\nlative incidence function) of severity onset continues to increase immediately after hospital admission, but arrives its change point at day 10 ( Figure 2 ). In contrast, the cumulative incidence of the competing risks event, that is, being discharged because of recovery, is much smaller during the high risk period of severity onset. However, such incidence dramatically increases from around day 12 to 29. To personalize the time-dependent risk assessment of severe progression, we incorporated CT image data with baseline information for the risk modeling ( Figure 3) . A total of 348 quantitative feature\n\n\n\nFile number: 265 index pair: (15702, 15713)\nthe SARS-CoV outbreak in 2003, with R0 approximately at 3.0. 17 Clinical characteristic analysis shows a significantly increased age as well as elevated numbers of underlying comorbidities in severe patients than those in non-severe patients, indicating that the age and comorbidity may be important risk factors for poor outcome. Contradictory to the previous report showing a higher incidence of COVID-19 in male patients, 5 recent data including ours, consistently showed a similar proportion of male and female patients with COVID-19. 11 The patients with COVID-19 also demonstrated a decreased lymphatic co\n\n\n\nFile number: 333 index pair: (3012, 3024)\nof an older population age structure for higher fatalities and critical cases. Going forward, demographically informed projections will better predict the COVID-19 burden and inform governments about targeted action. While population age structure is crucial for understanding the populations at the highest risk of mortality both across and within countries, it is also vital for understanding how much social distancing measures are required in each population to reduce the number of most critical cases and overload on the health system-aka \"flattening the curve\"(13). Our illustrations show that countries w\n\n\n\nFile number: 333 index pair: (6133, 6144)\nca (despite extensive trade and travel links with China), suggests that the young age structure of the continent may be protective of severe and thus detectable cases, or it may be undetected. Beyond age structure, there are large sex differences in mortality that need to be understood -with men at higher risk -some of which may be accounted for by the stark differences in smoking rates by sex in Asia. Distributions of underlying comorbidities such as diabetes, hypertension and COPD will likewise refine risk estimates. Until these more nuanced data are available, the concentration of mortality risk in th\n\n\n\nFile number: 333 index pair: (15839, 15851)\nr/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . This stylized example may serve, once more, to show why while population age structure is crucial for understanding the populations at the highest risk of mortality both across and within countries, it is also important for understanding how much social distancing measures are required in each population to reduce the number of most critical cases and overload on the health system-aka \"flattening the curve.\" 6 At this time of severe crisis, policy\n\n\n\nFile number: 340 index pair: (3050, 3059)\nn binding with ACE2. However, all proteins mentioned above are engineered in laboratory by recombinant expression system, not from real virus and the structure as whole of virion is thus still lacking. Furthermore, safety is one of the major factors that restricts virus study of SARS-CoV-2 due to a high risk of possible transmission, live viruses must be operated in Biosafety A 62-year-old male was admitted to our hospital on 15 January, 2020 with pneumonia, and was further diagnosed as COVID-19. An epidemiological investigation also confirmed a Wuhan travel history between 1 January and 14 January of \n\n\n\nFile number: 346 index pair: (1073, 1084)\n comorbidities. However, there was no cross-tabulation of factors, and so it is not clear how many patients in each age group had each comorbdity, nor how the risks associated with those co-morbidities interact with each other 3 . There is one small series of 18 patients with cancer, which suggests higher risks of intubation or death, but it is so small it difficult to draw robust conclusions, and the authors' conclusions have been criticised 4 . One other study suggests patients with a history of cancer have a higher risk of becoming infected with COVID. The data from CDC China have been used to simulat\n\n\n\nFile number: 346 index pair: (1290, 1301)\nach other 3 . There is one small series of 18 patients with cancer, which suggests higher risks of intubation or death, but it is so small it difficult to draw robust conclusions, and the authors' conclusions have been criticised 4 . One other study suggests patients with a history of cancer have a higher risk of becoming infected with COVID. The data from CDC China have been used to simulate a population and then develop a risk model based on that simulated population 5 ; Although a useful step, it almost certainly leads to \"double counting\" of risk (i.e. the increased risk of death in older patients an\n\n\n\nFile number: 346 index pair: (2787, 2798)\ns who have recently received chemotherapy may be at increased risk of death from influenza infection. There are no good models to estimate the risk of death in patients who have chemotherapy and acquire COVID infection, but there are parameters from previous viral pandemics, all of which point to a higher risk of death in patients with cancer or those who are immunosupressed. Medical practice does not always require precise estimates of risk. If a decision is binary (i.e. treat/ don't treat) then what we require is an estimate of risk that is good enough to make a decision, rather than being precise.The \n\n\n\nFile number: 346 index pair: (6596, 6607)\nthe risk of infection in patients is the same as the expected population-level infection rate, population level infection may take many months to occur. A more time limited horizon is given by estimating the number of cases of time, and integrating that number. It is clear that age is a significant risk factor for death in patients infected with COVID-19. In both this and previous viral pandemics, other comorbdities have been additional risk factors. There is reasonable evidence to suggest that patients who have cancer are probably at higher risk of death, and it seems unlikely to administration of chemo\n\n\n\nFile number: 346 index pair: (6737, 6848)\ns to occur. A more time limited horizon is given by estimating the number of cases of time, and integrating that number. It is clear that age is a significant risk factor for death in patients infected with COVID-19. In both this and previous viral pandemics, other comorbdities have been additional risk factors. There is reasonable evidence to suggest that patients who have cancer are probably at higher risk of death, and it seems unlikely to administration of chemotherapy will reduce that risk fur-. CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright\n\n\n\nFile number: 346 index pair: (7602, 7632)\nifficult, and not yet possible. Due to the epidemic nature of the disease, with exponential growth in cases, while the risks today may seem small, the predicted risks over the next few months are very much higher. There is consistent evidence to suggest that patients with a history of cancer are at higher risk of adverse outcomes when infected with COVID-19. A study of 138 patients with a baseline risk of ITU admission of 26%, 40% of those with a history of cancer required ITU admission 24 , but included only 10 patients with cancer. A review of 18 cancer patients who developed COVID-19 infection showed a higher risk of ha\n\n\n\nFile number: 346 index pair: (7915, 7926)\nf adverse outcomes when infected with COVID-19. A study of 138 patients with a baseline risk of ITU admission of 26%, 40% of those with a history of cancer required ITU admission 24 , but included only 10 patients with cancer. A review of 18 cancer patients who developed COVID-19 infection showed a higher risk of harm (defined as requiring ventilation in ITU or death) 7/18 (39%) than the general population 124/1572 (8%). 12 of these 18 were being followed up after surgery, while the 4 who had undergone chemotherapy or surgery within the last month had higher risk still 4 . There is some evidence that pat\n\n\n\nFile number: 346 index pair: (8173, 8267)\nwho developed COVID-19 infection showed a higher risk of harm (defined as requiring ventilation in ITU or death) 7/18 (39%) than the general population 124/1572 (8%). 12 of these 18 were being followed up after surgery, while the 4 who had undergone chemotherapy or surgery within the last month had higher risk still 4 . There is some evidence that patients with cancer might be at higher risk of infection 25 . . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . It is worth noting that the risks associated w\n\n\n\nFile number: 371 index pair: (5137, 5148)\n in Shenyang (unpublished) ( Figure 1A ); MTB infection rates were considerably higher among COVID-19 patients than among bacterial pneumonia patients (36.11% vs 20%; p = 0.047 Figure 1A ) and viral pneumonia patients (36.11% vs 16.13%; p = 0.024), suggesting that MTB infection status is a specific risk factor for SARS-COV-2 infection rather than for pneumonia in general. The rate of MTB infection in the bacterial and other viral pneumonia . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The\n\n\n\nFile number: 371 index pair: (9222, 9233)\nfurther validation. Based on our findings, we make the following recommendations for the management and treatment of patients with a history of MTB infection (LTBI or active TB) and possible SARS-CoV-2 coinfection. First, the medical and wider community should be informed that latent/active TB is a risk factor for SARS-CoV-2 infection, and those at risk should be encouraged to pay special attention to preventive measures. Ideally, this vulnerable group should be monitored regularly at community-based medical centers in situations when resources are available. Second, the MTB infection status (history and\n\n\n\nFile number: 429 index pair: (1563, 1575)\nconfirmed cases in China up to 20 February 2020 have mild-tomoderate disease -including both non-pneumonia and pneumonia cases; whilst 13.8% developed severe disease and 6.1% developed to a critical stage requiring intensive care 8 . In a study of clinical progression in 1,099 patients 4 , those at highest risk for severe disease and death included people over the age of 60 years and those with underlying conditions (including hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer). Assessing the severity of COVID-19 is critical to determine both the appropriateness of miti\n\n\n\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"print(\"Total number of possible text passages about risk factors: {}\".format(overall_processed_indices_count))","execution_count":136,"outputs":[{"output_type":"stream","text":"Total number of possible text passages about risk factors: 6796\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"In total we found many possible text passages, where some are really about risk factors of covid 19 and others are not.\n\nAn example of a useful text extract is:\n\"\"\"\nFile number: 60 index pair: (12790, 12801)\nthe . https://doi.org/10.1101/2020.03.21.001586 doi: bioRxiv preprint Clinical investigations have suggested that patients with cardiac diseases, hypertension, or diabetes, who are treated with ACE2-increasing drugs including inhibitors and blockers show increased expression of ACE2 and thus are at higher risk of getting the SARS-CoV2 infection (26) . Also there are studies on the regulatory role of miRNA hsa-mir-27b-3p described in ACE2 Signaling (27) . The results of the present study suggest a strong correlation between miRNA hsa-mir-27b-3p and ACE2 which needs to be confirmed experimentally in SARS-C\n\"\"\"\n\nAnd one example of a bad extract with respect to risk factors is:\n\"\"\"\nFile number: 239 index pair: (199, 203)\n Severe cases of coronavirus disease 2019 (COVID-19) rapidly develop acute respiratory distress leading to respiratory failure, with high short-term mortality rates. At present, there is no reliable risk stratification tool for non-severe COVID-19 patients at admission. We aimed to construct an effective model for early identifying cases at high risk of progression to severe COVID-19. China were included retrospectively. All patients with non-severe COVID-19 during hospitalization were followed for\n\"\"\"\n\n\nIf we want to print more context for a given filenumber we can use the code in the next cell."},{"metadata":{},"cell_type":"markdown","source":"##### Show an extract based on start and end index for a file number"},{"metadata":{"trusted":true},"cell_type":"code","source":"file_number = 239\nstart_idx = 0\nend_idx = 2000\n\nprint_text(file_number, start_idx, end_idx)","execution_count":137,"outputs":[{"output_type":"stream","text":" COVID-19, the disease caused by SARS-CoV-2 virus that surfaced in Wuhan, China in early December 2019, is now plaguing the world. Due to its high intra-human transmission nature, there were more than one hundred and fifty thousand confirmed cases around the world by 15 March, 2020 . In view of the rapid surge of infected patients, World Health Organization (WHO) has declared the viral disease a pandemic on 11 March, 2020. To contain COVID-19, a prompt and accurate diagnostic test is necessary. While new tests have been proposed, the SARS-CoV-2 nucleic acid test is currently the standard diagnostic criterion used by most countries. However, contradictory to clinical symptoms and chest CT scanning, many patients have shown false negative testing results during their initial clinic visits. As a result, hospital admission and treatment have been delayed for many of them. These patients have been stranded in outpatient clinics or isolation zones, increasing the risk of exposure of other non-COVID-19 patients and medical workers. Their confirmed diagnoses of COVID-19 have since raised concerns for the validity and reliability of the test. To better contain COVID-19, it is essential to understand the factors that influence the test's false-negative incidence rate. Several factors contribute to a relatively high false-negative incidence in the nucleic acid test: (1) the sensitivity of the detection kits; (2) inappropriate clinical sampling from patients; (3) the original viral load. The first factor is a concern for the manufacturers while the second can be remedied through staff training. The last factor, however, links to the progression of COVID-19, which is patient-specific. In other words, the viral load has demonstrated individual heterogeneity, and has gone beyond doctors' subjective evaluation. Hence, it is essential to 5 conduct the test when viral load is high. Consequently, the right timing for the test will avoid repeated sampling, reduce exposure risk for outp\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"One drawback of this approach applied to the given data is the occurrence of false positives, this means our patterns match for passages which might be irrelevant.\nThis can for example happen when a document is not about covid 19 and hence the passage doesn't mention risk factors for covid 19. Maybe a document is about another virus, which is more or less similar to Covid 19, which makes it hard to judge if the paper is relevant.\nBelow we are looking for files which might not directly relate to Covid-19"},{"metadata":{"trusted":true},"cell_type":"code","source":"def is_file_directly_related(filenumber):\n    data = json.load(open(files[filenumber]))\n    synonyms_for_covid_19 = [\n        r\"(covid)\",\n        r\"(sars)\",\n        r\"(cov(.){0,4}2)\",\n        r\"(novo)\",\n        r\"(corona)\",\n    ]\n    body_text = \"\"\n    for i in range(len(data[\"body_text\"])):\n        body_text += \" \" + data[\"body_text\"][i][\"text\"].lower()\n    body_text = re.sub(' +', ' ', body_text)\n    \n    at_least_one_match = False\n    for synonym_pattern in synonyms_for_covid_19:\n        matches = [(m.start(0), m.end(0)) for m in re.finditer(synonym_pattern, body_text)]\n        if len(matches) != 0:\n            return True\n    return False\n\nnot_directly_related_files = []\nfor i in range(len(files)):\n    if not is_file_directly_related(i):\n        not_directly_related_files.append(i)\nprint(\"Found {} files which might not directly relate to Covid-19\".format(len(not_directly_related_files)))","execution_count":138,"outputs":[{"output_type":"stream","text":"Found 3558 files which might not directly relate to Covid-19\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"### To investigate some of the potentially not directly related papers we can print their title and body text."},{"metadata":{"trusted":true},"cell_type":"code","source":"print_title(not_directly_related_files[1])","execution_count":139,"outputs":[{"output_type":"stream","text":"Restriction Factor in Yeasts 2 3\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"print_body_text(not_directly_related_files[1])","execution_count":140,"outputs":[{"output_type":"stream","text":" To differentiate between models where Xrn1p restricts L-A through a passive 158 mechanism that is incidental to its inherant exonuclease activity, or through an active 159 mechanism where Xrn1p evolves to optimally suppress L-A replication, we first looked 160 for evidence of positive selection (dN/dS > 1) within the genes encoding the major 161 components of the SKI complex, the exosome, and Xrn1p ( Fig 1B) . Importantly, cerevisiae, S. paradoxus, S. mikatae, S. kudriavzevii, S. arboricolus, and S. bayanus) 171 [44] [45] [46] and created a multiple sequence alignment. We then analyzed each alignment 172 for evidence of codons with dN/dS > 1 using four commonly employed tests for positive 173 selection [47, 48] . We see some evidence for positive selection of specific codon sites in 174 several of these genes, however, only XRN1 and the exosome subunit gene RRP40 175 passed all four tests ( Fig 1C; Table S1 ). Other genes are determined to be under surprising for a critical and conserved gene involved in RNA quality control, but 203 consistent with the signatures of positive selection which suggest that certain parts of 204 this protein are highly divergent between species. We next used a functional and quantitative assay to confirm the species-specific 229 effects of XRN1 on virus replication. This assay exploits the dsRNA \"killer virus\" (also 230 known as M virus). The killer virus is a satellite RNA of L-A and is totally dependent on 231 L-A proteins for replication. It uses L-A-encoded proteins to encapsidate and replicate 232 its genome, and to synthesize and cap its RNA transcripts [12] . The killer virus encodes 233 only a single protein, a secreted toxin referred to as the killer toxin [19, 55, 56] . The result 234 is that \"killer yeast\" colonies, i.e. those infected with both L-A and the killer virus, kill 235 neighboring cells via the diffusion of toxin into the surrounding medium ( Fig 2C) . has been shown previously that Xrn1p can inhibit the expression of the killer phenotype 239 by degrading uncapped killer virus RNAs [14, 57] . Therefore, we use the presence and 240 size of kill zones produced by killer yeasts as a quantitative measurement of killer virus 241 RNA production in the presence of each Xrn1p ortholog. A strain of S. cerevisiae lacking XRN1, but harboring both the L-A and killer virus 244 (xrn1 L-A + Killer + ), was complemented with each XRN1 ortholog. Clonal isolates from 245 each complemented strain were grown to mid-log phase, and 6 x 10 5 cells were spotted 246 onto an agar plate seeded with a lawn of toxin-sensitive yeast. After several days' 247 incubation at room temperature, kill zones around these culture spots were measured 248 and the total area calculated. The transformation of xrn1 L-A + Killer + with S. cerevisiae 249 XRN1 produced an average kill zone that covered 0.68 cm 2 (n = 14). However, 250 transformation with XRN1 from S. mikatae, S. bayanus, or S. kudriavzevii produced 251 significantly larger kill zones covering 0.92 cm 2 (n = 11), 0.96 cm 2 (n = 17) and 0.97 cm 2 252 (n = 17), respectively. The kill zone produced by xrn1 L-A + Killer + yeast expressing S. 253 cerevisiae XRN1 was significantly smaller than those produced by yeast expressing any 254 of the other XRN1 ortholog (Tukey-Kramer test, p<0.05) (Figs 2D). The smaller kill 255 zones in the strain expressing S. cerevisiae XRN1 are consistent with lower levels of 256 killer and L-A derived RNAs. In summary, this assay also supports a species-specific 257 restriction phenotype for XRN1. It has been observed that over-expression of XRN1 can cure S. cerevisiae of the 260 L-A virus, presumably by degrading viral RNA so effectively that the virus is driven to 261 extinction [8, 28] . Therefore, we developed a third assay to test the ability of XRN1 262 orthologs to control L-A, in this case by assessing their ability to cure S. cerevisiae of the 263 All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint virus. Plasmids expressing HA-tagged and untagged Xrn1p were transformed into a 264 killer strain of S. cerevisiae with its genomic copy of XRN1 intact. This was followed by 265 the analysis of more than 100 purified clones for virus curing, that is, the absence of the 266 killer phenotype as indicated by the loss of a kill zone when plated on a lawn of sensitive 267 yeast. Importantly, the introduction of an empty plasmid fails to produce any cured 268 clones (n = 103) (Figs 3A and 3B). Provision of an additional copy of S. cerevisiae XRN1 269 cured 49% of clones (n = 159) (Figs 3A and 3B). Cured clones remained cured (i.e. non-270 killers) when purified and tested again for their ability to kill sensitive yeasts (n = 20). Over-expression of XRN1 from S. mikatae, S. kudriavzevii, and S. bayanus was unable 272 to efficiently cure the killer phenotype, resulting in only 12% (n = 129), 8% (n = 120), and 273 9% (n = 123) cured clones, respectively ( Fig 3A, blue bars). The loss of L-A from cured 274 strains was also verified by RT-PCR. We detected no L-A or killer RNAs within the four 275 cured clones analyzed ( Fig 3C) . These data show that XRN1 from all Saccharomyces 276 species have the ability to cure the killer phenotype, however, XRN1 from S. mikatae, S. kudriavzevii, and S. bayanus is considerably less efficient than S. cerevisiae XRN1. Taken together, we show that viral restriction by XRN1 is species-specific. These data 279 contradict a model where viral restriction is merely incidental to the RNA quality control 280 functions of XRN1, but is rather something that can be refined through sequence 281 evolution in XRN1. We next tested the presumption that the XRN1 orthologs are functionally 296 equivalent for cellular processes when expressed within S. cerevisiae. We first 297 confirmed that XRN1 orthologs successfully complemented the severe growth defect of 298 S. cerevisiae xrn1, by measuring the doubling time of S. cerevisiae xrn1 with or 299 without a complementing XRN1-containing plasmid ( Fig 4A) and MEME (green). See Table S1 for a list of all sites. The seven residues that To define the importance of the two regions that we identified as containing 375 signatures of positive selection, we replaced portions of S. kudriavzevii XRN1 with the 376 equivalent portions of S. cerevisiae XRN1, and assayed for a region of S. cerevisiae 377 XRN1 that would convey the ability to cure the killer phenotype. We found that an XRN1 378 chimera encoding the last 775 amino acids from S. cerevisiae (Sc-775) was sufficient to 379 cure 56% of clones analyzed, and this was very similar to S. cerevisiae XRN1 (57%) (Fig 380 5D ). Conversely, when the last 777 amino acids from S. kudriavzevii (Sk-777) were 381 used to replace the same region within S. cerevisiae XRN1, only 9% of clones were 382 cured ( Fig S3) . This focused our construction of further chimeras to the second half of 383 the protein, which also contains all of the codons under positive selection and has less 384 amino acid conservation between S. cerevisiae and S. kudriavzevii (82% protein identity, amino acids of S. cerevisiae Xrn1p were unable to convey efficient L-A restriction to S. kudriavzevii Xrn1p (Fig S3) . For this reason, we focused further chimeric analysis on the 390 region encompassing the D1-D3 domains (Fig 5A-C) , as defined previously [59] . We 391 swapped into S. kudriavzevii Xrn1p the D2-D3, D1, or D1-D3 domains of S. cerevisiae 392 Xrn1p, and saw increasing rescue of the ability to cure the L-A virus ( Fig 5D) . All 393 chimeric XRN1 genes were functionally equivalent with respect to their cellular functions, 394 as all were able to establish normal growth and benomyl resistance in S. cerevisiae 395 xrn1 ( Fig S4) . Therefore, the species-specificity domain maps predominantly to D1, 396 with contribution from the neighboring D2 and D3 domains as well. Together, our data 397 suggest that the exonuclease activity of Xrn1p is important for virus restriction and is 398 preserved across species, but that evolution has tailored a novel virus interaction The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint encoded L-A Gag was immunoprecipitated in the presence of Xrn1p-HA from 443 either S. cerevisiae or S. kudriavzevii using beads with (+Ig) or without (-Ig) anti-444 Gag antibody present. Adh1p was used in all panels as a loading control to 445 ensure equal input of total protein and the specificity of immunoprecipitation. Confirmation of the species-specific restriction of Xrn1p using a newly 448 described totivirus from S. kudriavzevii. We next wished to test our findings against other related yeast viruses. Indeed, 451 the S. cerevisiae totivirus L-A-lus has been shown to have limited susceptibility to XRN1 452 from a different strain of S. cerevisiae [28] . We also wanted to test viruses of other residue required for cap-snatching (H154), a -1 frameshift region, packaging signal, and in S. cerevisiae (Fig 3) . We did not observe any virus curing by any orthologs of Xrn1p, 506 but believe that this could be because the high-copy plasmids that we used in this 507 experiment in S. cerevisiae are unable to drive Xrn1p expression in S. kudriavzevii high 508 enough to actually cure the virus. However, we have observed previously that Xrn1p can 509 reduce the abundance of totivirus RNAs (Fig 2A) , so we further analyzed the XRN1-510 transformed clones of S. kudriavzevii for changes in SkV-L-A1 RNA levels using reverse 511 transcriptase quantitative PCR (RT-qPCR). Total RNA was extracted from clones of S. kudriavzevii and converted to cDNA using random hexamer priming. cDNA samples 513 were amplified using primers designed to specifically target SkV-L-A1 GAG and the 514 cellular gene TAF10. The empty vector control was used as the calibrator sample, and 515 TAF10 expression was used as the normalizer to calculate the relative amount of SkV-L-516 A1 RNAs present within each XRN1 expressing S. kudriavzevii cell line using the 517 comparative CT method [65] . We found that expression of XRN1 from S. kudriavzevii (n 518 = 10) reduced the relative levels of SkV-L-A1 RNAs by 40% (Fig 7E) , even though this Xrn1p was expressed at the lowest levels ( Fig 7D) . This is in contrast to XRN1 from S. 520 mikatae (n = 9) and S. bayanus (n = 8) that only showed a 13% increase or 15% 521 decrease in SkV-L-A1 RNAs, respectively. S. cerevisiae XRN1 was able to reduce SkV-522 L-A1 RNAs by 27% and is noteworthy due to the close evolutionary relationship between 523 SkV-L-A1 and other L-A-like viruses from S. cerevisiae ( Fig S6) . These data suggest 524 that Xrn1p is a species-specific restriction factor in different Saccharomyces yeasts, and 525 that coevolution of totiviruses and yeasts has specifically tailored the potency of Xrn1p to 526 control the replication of resident viruses within the same species. 527 528 All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint important for controlling the abundance of totivirus RNAs. We find that XRN1 and the 538 virus the best. The exact nature of the host-virus protein-protein interaction that is driving 539 this evolutionary arms race is not clear. To thwart XRN1, the totiviruses are known to 540 synthesize uncapped RNAs with an exposed 5' diphosphate, which is a suboptimal 541 substrate for Xrn1p-mediated decay [24] . Further, it has been shown that the totivirus 542 Gag protein has a cap-snatching activity that cleaves off caps from host mRNAs and 543 uses them to cap viral transcripts, protecting them from Xrn1p degradation [12, 14] . We 544 have found that Xrn1p interacts with L-A Gag, and that this interaction is not mediated by 545 the presence of single-stranded RNAs. What remains unknown is whether Xrn1p is 546 targeting Gag as part of the restriction mechanism, or whether Gag is targeting Xrn1p as 547 a counter defense. As we did not observe an obvious species-specific differences in the 548 interaction between Xrn1p and L-A Gag by coimmunoprecipitation, we cannot clearly 549 define the observed role of sequence variation in Xrn1p. This may be because of the 550 low sensitivity of our assay system, or because direct binding of Xrn1p by L-A Gag is 551 ubiquitous and that the rapid evolution of XRN1 results from another intriguing facet of 552 virus-host interaction and antagonism. However, we now know that the interaction 553 All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint between L-A and Xrn1p goes beyond the simple recognition of L-A RNA by Xrn1p. We 554 can speculate that Xrn1p may compete with Gag for access to uncapped viral RNAs as 555 they are extruded into the cytoplasm, or that interaction with unassembled Gag allows 556 the recruitment of Xrn1p to sites of virion assembly resulting in viral RNA degradation. Alternately, it is possible that the target of Xrn1p is simply L-A RNA, and that the The literature suggests that Xrn1p is a widely-utilized restriction factor against 564 viruses, as it has been reported to have activity against mammalian viruses [9,16], yeast 565 viruses [8, 24] , and plant viruses [53] . The potent 5'-3' exonuclease activity of Xrn1p has 566 resulted in viruses developing a rich diversity of strategies to protect their RNAs. For 567 instance, Hepatitis C virus recruits MiR-122 and Ago2 to its 5' UTR to protect its RNA 568 genome from Xrn1p degradation [7, 16] . The yeast single-stranded RNA narnavirus uses 569 a different strategy to protect its 5' terminus, folding its RNA to form a stem-loop 570 structure that prevents Xrn1p degradation [8] . In some cases, viruses even depend on 571 Xrn1p to digest viral RNA in a way that benefits viral replication, for example, preventing proteins that initiate endonucleolytic cleavage of host mRNAs, revealing exposed 5' 578 monophosphates that are substrates for Xrn1p degradation. This is thought to interfere 579 All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint \"decoys\", and viral RNA pseudoknots are all utilized to prevent Xrn1p-mediated viral 584 RNA destruction [7, 8, [12] [13] [14] [15] [16] [17] [18] (Fig 2) , virus loss (Fig 3) , or a reduction in viral RNA (Fig 2 and Fig 7) . Signatures of 624 positive selection that we have detected in Saccharomyces XRN1 are also consistent 625 with a host-virus equilibrium that is in constant flux due to the dynamics of a back-and-626 forth evolutionary conflict (Fig 2 and Fig 6) . There are several examples of mammalian housekeeping proteins engaged in 629 evolutionary arms races with viruses. (By \"housekeeping\" we refer to proteins making 630 critical contributions to host cellular processes, as opposed to proteins dedicated to 631 All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint assembled plasmids selected for by growth on complete medium (CM) -leucine. The 657 XRN1 open reading frame (HA-tagged and untagged) from S. mikatae, S. bayanus, or S. kudriavzevii was introduced into pPAR219 between the 5' and 3' UTRs from S. 659 cerevisiae XRN1 using recombineering to produce pPAR225, pPAR226, and pPAR227, 660 respectively. As a negative control, NUP133 was cloned into the pPAR219 plasmid 661 backbone to produce pPAR221, which was used to allow growth of xrn1 on medium 662 lacking leucine without XRN1 complementation. The LEU2 gene was replaced by TRP1 663 using recombineering techniques to produce the plasmids pPAR326, pPAR327, 664 pPAR328, and pPAR329. Using PCR and recombineering, we also constructed The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint sec. The dsRNA was eluted from the column by the addition of 100 l of 0.15 mM EDTA 706 (pH 7.0) and incubation at 65 o C for 5 min before centrifugation at 16,000 x g for 30 sec. dsRNA that was extracted from 1 x 10 9 yeast cells using our rapid extraction of viral 710 dsRNA protocol was used as template for superscript two-step RT-PCR (Thermo 711 Fisher). cDNA was created using a primer specific for the negative strand L-A genomic The same primers were used to detect L-A and killer virus specific cDNAs using PCR 724 with Taq polymerase (New England Biolabs). We assayed Ty1 retrotransposition in S. cerevisiae xrn1, using the previously 728 described Ty1 retrotransposition reporter system [89] , and confirmed that XRN1 deletion 729 causes a dramatic reduction in Ty1 retrotransposition (~50-fold) [35] . To test the effect of 730 All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint volume of log-phase yeast cells as per manufacturers instructions or by bead beating as of the analysis, two models of codon frequencies (F61 and F3x4) and multiple seed 758 values for dN/dS () were used (Table S1) All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint YPD plates containing 15 g ml -1 of benomyl were prepared as described previously The curing of the killer phenotype was measured by transforming S. cerevisiae BJH006 804 with approximately 100 ng of plasmid encoding various XRN1 genes using the LiAc 805 method. The addition of 1000 ng or as little as 10 ng of plasmid had no affect on the 806 percentage of colonies cured using this assay. After 48 h of growth, colonies were 807 streaked out and grown for a further 48 h. Clonal isolates of killer yeasts were patched 808 onto a YPD \"killer assay\" plate (see kill zone measurement protocol) that were 809 previously inoculated with S. cerevisiae K12, and incubated at room temperature for 72 810 h. The presence or absence of a zone of inhibition was used to calculate the percentage 811 of killer yeast clones cured of the killer phenotype. Xrn1p structural modeling 814 PHYRE was used to create a template-based homology model of S. cerevisiae Xrn1p 815 using the solved structure of K. lactis Xrn1p as a template [58, 59] . The structure was 816 determined with an overall confidence of 100% (36% of aligned residues have a perfect 817 alignment confidence as determined by the PHYRE inspector tool), a total coverage of 818 81%, and an amino acid identity of 67% compared to K. lactis Xrn1p. PDB coordinates 819 for the modeled structure can be found in File S1. Structural diagrams were constructed 820 using MacPyMOL v7.2.3. Co-immunoprecipitation of Xrn1p and L-A Gag. Strains were grown in CM lacking the appropriate amino acids in order to retain the 824 relevant plasmids. For co-immunoprecipitations involving L-A Gag-V5 and Xrn1p-HA, 50 825 mL cultures (CM -tryptophan -leucine, 2% raffinose) were used to inoculate 500 mL 826 cultures (CM -tryptophan -leucine, 2% galactose) at OD600 ~0.1. Cells were harvested 827 All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. Schmitt MJ, Breinig F. Yeast viral killer toxins: lethality and self-protection. Nat All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. n/a n/a All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint 3' Gly Phe Arg Gly Leu Gly -1 frame 0 frame 3' L-A-lus G -5.9 kCal/mol 3' SkV-L-A1 G -2.1 kCal/mol A Figure All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint Doubling time (min) All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/069799 doi: bioRxiv preprint\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"overall_processed_indices_count = doit(only_directly_related_files=True)","execution_count":141,"outputs":[{"output_type":"stream","text":"File number: 12 index pair: (3896, 3907)\ncal authority, is essential 245 for emergency management. outbreak control. The study also found that uptake of prevention practices was poorer among older 247 members of the public, which warrants serious attention. It has been found that older 248 adults affected by 2019-nCoV are likely to have a higher risk of complications and 249 mortality (4). There is a need to find out whether a lack of appropriate prevention 250 practices among people of older age is due to knowledge deficiency or to their being 251 out-of-reach of current public health intervention. The finding that nearly 15% of people would b\n\n\n\nFile number: 15 index pair: (7902, 7918)\ns associated with inferior outcome 6 . Interestingly, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Given that Case 2 has a history of long-term use of glucocorticoids, which is the high-risk factor for severe infection and progression, overall, the severity of Case 2 was much optimistic than average status in her age group, since it was reported elder people infected SARS-CoV-2 have much worse prognosis 10 . Furthermore, though his another relative also got fever at the time of visit, the vir\n\n\n\nFile number: 71 index pair: (7439, 7450)\n be older with higher levels of cardiac injury markers and higher levels of systematic inflammation markers. Patients with higher NT-proBNP (above 88.64 pg/mL) level had lower cumulative survival rate. After adjusting for potential cofounders in separate modes, NT-proBNP presented as an independent risk factor of in-hospital death in patients with severe COVID-19. All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1\n\n\n\nFile number: 96 index pair: (29601, 29677)\n, but the curve will also be broader. Some containment strategies could even be counterproductive in other ways. For instance, the simple model used in Fig 12 does not account for age-stratification. In diseases such as COVID-19, where children develop mostly mild forms, while elderly people have a high risk of dying. (Zimmermann Curtis 2020) Hence, containment of high-risk groups, like elderly people in nursing homes (see the Washington State example) is highly effective in protecting them from becoming infected and reducing the pool that would have to reach herd immunity. A substantial increase in the duration of the epidemic, however, might make effective containme\n\n\n\nFile number: 96 index pair: (31225, 31234)\nrictions are discussed to be lifted on 04-12 (day 100). The model predicts that such an intervention would reduce the number of deaths in New York and Detroit (and possibly some other parts of the U.S., but the virus would linger on for another two months, so that it would not be safe for (elderly) high-risk people to participate in this year's Easter activities. Until a vaccine will become available, the only pharmacological strategy to reduce the number of deaths is to reduce the damage the infection (and immune system) does, e.g., by reducing the initial viral load, (Chu 2004) and making sure that p\n\n\n\nFile number: 102 index pair: (8205, 8214)\nnation for this is that the prevalence of malignancy was higher in males. Liang et al. [19] found that in severe COVID-19 patients, those with cancer had poorer outcomes from COVID-19. In addition, more men in our study were co-infected with bacteria or influenza virus, which may somewhat result in high risk. Rothberg et al. [20] reported that bacterial infection was a common pulmonary complication of influenza. We found that positive influenza A antibody were detected in 5 men patients but not in women. Otherwise a higher rate of increased procalcitonin was also observed in men. These findings suggest\n\n\n\nFile number: 105 index pair: (14631, 14642)\ny to be older, male, with temperature over 38.5 o C, symptom of dyspnoea, underlying cardiovascular disease, and longer waiting period from onset of symptom to hospital admission, compared to those not admitted to the ICU. This suggests that age, sex, high fever, admission time and co-morbidity are risk factors for disease severity. Compared with non-ICU patients, patients who received ICU care had numerous laboratory abnormalities. These abnormalities suggest that SARS-Cov-2 infection can be associated with cellular immune deficiency, coagulation activation, myocardial injury, hepatic injury and kidney \n\n\n\nFile number: 105 index pair: (17248, 17259)\nical manifestations occur, including a spectrum form T cell deficiency to symptoms of digestive system involvement. Older age, male, fever over 38.5 o C, symptom of dyspnoea, the presence of underlying cardiovascular disease, and longer waiting period from onset of symptom to hospital admission are risk factors associated with the severity of disease. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.0\n\n\n\nFile number: 106 index pair: (11096, 11107)\nof studies have shown that diabetic patients had higher mortality and morbidity of severe medical illness, such as myocardial infarction, and high FBG plays an independent predictive role in hospitalized non-diabetic patients as well [17, 18, 19] . Diabetes has also been identified as a significant risk factor for severe disease following respiratory tract infections [20] . Several studies demonstrated that diabetes was associated with increased the risks of severity and mortality after SARS-CoV and MERS-CoV . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has grant\n\n\n\nFile number: 112 index pair: (1468, 1479)\nes in mainland China, including 3,267 deaths. Internationally, a total of 288,275 confirmed cases have been reported from 186 countries outside of, including 9,517 deaths. Considering the global public health threat posed by COVID- 19 , unraveling the prognostic factors for patients, especially the risk factors of mortality associated with COVID-19, has important implications for clinical practice and is urgently warranted. Studies have indicated that severe cases tend to be older in age [6] [8] and are more likely to have had pre-existing medical conditions, including but not limited to hypertension [3]\n\n\n\nFile number: 112 index pair: (6655, 6666)\nd to rule out the multicollinearity concern before fitting any model. Univariate weighted Cox models were performed for each of the comorbidity of interest. Multivariate weighted Cox model was used to determine if pre-existing comorbidity yielded prognostic hazard information. Other than the common risk factors (age, gender and history of surgery), the multivariate model also adjusted for location of diagnosis (in vs. outside of Hubei Province) and early period of pandemic (after vs. before January 11 th , 2020 when no-intervention was taken by the government) [20] . Although matching was based on age an\n\n\n\nFile number: 112 index pair: (13040, 13051)\ndeath risk of COVID-19: one additional pre-existing comorbidity led to an estimated 29% increase of death risk (p=0.01). However, after adjusting for confounders, CHD was the only significant risk factor for COVID-19 mortality after adjusting for confounders. Patients with CHD had 92% significantly higher risk of mortality in COVID-19, compared to patients without CHD (p=0.009). The estimated median survival times for those with CHD was 13 days (95% CI: 11-23 days), at lease 67 days shorter than those without CHD (p<0.001). Moreover, we estimated that COVID-19 patients with hypertension had 43% higher de\n\n\n\nFile number: 138 index pair: (13368, 13377)\nh the increase of newly confirmed and severe cases, the management of severe patients brings huge challenge in efficiently controlling the COVID-19 outbreak. Some patients progressed rapidly with ARDS and subsequent multiple organ dysfunction syndrome (MODS). 2 Early identification of patients with high risk to develop ARDS or MODS and risk stratification management might be helpful to reduce mortality. In our cohort, the prevalence of severe NCP was 10.6%, which was . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the prep\n\n\n\nFile number: 138 index pair: (19653, 19664)\nng hospitalization were not included in the analysis. More comprehensive investigation of the relationship between CT characteristics and cytokine storm induced by COVID-2019 needs to be performed. In conclusion, our results showed that higher NLR and CT severity score on admission were independent risk factors for short-term progression in patients with NCP. The CT findings in patients with NCP were associated with inflammatory levels and both them have the potential to predict disease progression. Imported and nonimported patients outside Wuhan should be managed equally, and early admission is required\n\n\n\nFile number: 141 index pair: (17051, 17060)\nt patterns could contribute to different attack rates by age group, but we include age-specific contact patterns in the model. Second, we assume that, as a result of more severe symptoms at older ages, all cases in symptomatic individuals aged 80 years were reported. We cannot confirm this, but the high risk of death from Covid-19 amongst the elderly was reported very early on [3] , so we believe that most old people with symptoms sought care. If this assumption is wrong, mortality in our study would be overestimated. Sensitivity analyses show a linear relation between the ascertainment proportion for \n\n\n\nFile number: 159 index pair: (7756, 7767)\nrare. Chest computed tomography scan showing ground glass opacity of diagnosed patients account for 63.3%, whereas the severe pneumonia up to 76.2%, these were inconsistent with other studies 12 data suggested that gender may not be an influence factor in 2019-nCov infection, yet advanced age was a risk factor for viral infection and poor prognosis. Our data of laboratory detection indicated that the white blood cells and C-reactive protein level were elevated in severe case series and the lymphocytes were decreased. The results suggested that severe pneumonia may be accompanying bacterial infection and \n\n\n\nFile number: 159 index pair: (8350, 8361)\nal infection and immune deficiency may be also a risk factor for unfavourable prognosis in patients 13 . In addition, alanine transaminase (ALT), aspartate transaminase (AST) and creatinine (CR) were elevated in the patients of severe pneumonia. The results suggested that 2019-nCov may be carries a risk factor of impaired liver and kidney function. In summary, our data provide more information that advanced age, lower lymphocytes levels at the diagnosed COVID-19 patients may be a risk factor for unfavourable prognosis. The white blood cells and C-reactive protein level elevated in severe COVID-19 patient\n\n\n\nFile number: 159 index pair: (8535, 8546)\nnine (CR) were elevated in the patients of severe pneumonia. The results suggested that 2019-nCov may be carries a risk factor of impaired liver and kidney function. In summary, our data provide more information that advanced age, lower lymphocytes levels at the diagnosed COVID-19 patients may be a risk factor for unfavourable prognosis. The white blood cells and C-reactive protein level elevated in severe COVID-19 patients may be accompanying bacterial infection. 2019-nCov may be carries a risk factor of impaired liver and kidney function. . CC-BY-NC-ND 4.0 International license It is made available und\n\n\n\nFile number: 211 index pair: (6976, 6987)\nbetween survivors and non-survivors. Non-survivors showed significantly higher white blood cell and neutrophil count, NLR, SII, CRP, procalcitonin, and D-dimer, and lower red blood cell, lymphocyte, and platelet count compared to survivors (Table 1) . The independent predictors were identified from risk factors relating to adverse clinical outcome by logistic regression model. As indicated in table 2, age, neutrophil count, platelet count, and CRP were found to be independent predictors of adverse outcome. Hosmer and Lemeshow test showed a good model adequacy ( 2 =6.64, p=0.576). To determine and compar\n\n\n\nFile number: 211 index pair: (7171, 7186)\nte, and platelet count compared to survivors (Table 1) . The independent predictors were identified from risk factors relating to adverse clinical outcome by logistic regression model. As indicated in table 2, age, neutrophil count, platelet count, and CRP were found to be independent predictors of adverse outcome. Hosmer and Lemeshow test showed a good model adequacy ( 2 =6.64, p=0.576). To determine and compare the accuracy of these factors in adverse outcome prediction, ROC curve analysis was performed and the difference in AUCs was tested. Figure 1 ). The AUC of CRP was significantly higher than that of\n\n\n\nFile number: 211 index pair: (7322, 7337)\nome by logistic regression model. As indicated in table 2, age, neutrophil count, platelet count, and CRP were found to be independent predictors of adverse outcome. Hosmer and Lemeshow test showed a good model adequacy ( 2 =6.64, p=0.576). To determine and compare the accuracy of these factors in adverse outcome prediction, ROC curve analysis was performed and the difference in AUCs was tested. Figure 1 ). The AUC of CRP was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z = 2.09, p =0.028), and platelet count (z = 5.65, p <0.001) for adverse outcome prediction. With a cut-off .\n\n\n\nFile number: 211 index pair: (7593, 7608)\naccuracy of these factors in adverse outcome prediction, ROC curve analysis was performed and the difference in AUCs was tested. Figure 1 ). The AUC of CRP was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z = 2.09, p =0.028), and platelet count (z = 5.65, p <0.001) for adverse outcome prediction. With a cut-off . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint CC-BY-NC-ND 4.0 International license I\n\n\n\nFile number: 211 index pair: (9731, 9746)\nbout the prognostic value of CRP in patients with COVID-19. The pathological mechanism of COVID-19 has not been fully uncovered. In this study, the median age of non-survivors was 71 (64-80) years, significantly higher than 57 (40-69) years in survivors. Further, age was an independent predictor of adverse outcome and discriminator of severe/critical illness, which suggested that old people are more vulnerable to SARS-CoV-2 and more likely to develop severe/critical disease. 5, 6, 8 Elevated neutrophil count was observed in patients with severe illness compared to those with non-severe illness. 7 In this stu\n\n\n\nFile number: 211 index pair: (16327, 16342)\ndisplay the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.21.20040360 doi: medRxiv preprint 2 0 Receiver operating characteristic (ROC) curves of age, neutrophil count, platelet count, and C-reactive protein for adverse outcome prediction. The area under the curve (AUC) of age, neutrophil count, platelet count, and C-reactive protein for predicting adverse outcome was 0.833, 0.820, 0.678, and 0.896, respectively. The AUC of C-reactive protein was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z\n\n\n\nFile number: 211 index pair: (16466, 16481)\n020.03.21.20040360 doi: medRxiv preprint 2 0 Receiver operating characteristic (ROC) curves of age, neutrophil count, platelet count, and C-reactive protein for adverse outcome prediction. The area under the curve (AUC) of age, neutrophil count, platelet count, and C-reactive protein for predicting adverse outcome was 0.833, 0.820, 0.678, and 0.896, respectively. The AUC of C-reactive protein was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z = 2.09, p =0.028), and platelet count (z = 5.65, p <0.001) for adverse outcome prediction. . CC-BY-NC-ND 4.0 International license It is m\n\n\n\nFile number: 211 index pair: (16706, 16721)\nount, platelet count, and C-reactive protein for predicting adverse outcome was 0.833, 0.820, 0.678, and 0.896, respectively. The AUC of C-reactive protein was significantly higher than that of age (z=2.05, p=0.041), neutrophil count (z = 2.09, p =0.028), and platelet count (z = 5.65, p <0.001) for adverse outcome prediction. . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.21.20040360 doi: med\n\n\n\nFile number: 243 index pair: (12211, 12222)\neatment of adenovirus pneumonia 42 . While other studies revealed that CRRT was a risk factor for mortality in patients with MERS-CoV 16 Although CRRT treatment improved patient survival, 54.5% of patients with CRRT treatment died during our follow-up. In patients with CRRT, we further explored the risk factors for death for better management and treatment. We derived that older age, and higher levels of IL-1, IL-2 receptor, hs-cTnI, and NT-proBNP were independently associated with a higher allcause mortality in patients with CRRT. IL-1 is known as a lymphocyte-stimulating factor, produced by activated\n\n\n\nFile number: 263 index pair: (374, 458)\ns outbreak has quickly became a global public health issue, with a total of 168,019 infected, 6,610 deaths and 148 countries affected as of Mar 16, 2020 (World Health Organization, WHO 1 ). One of main challenges facing its medical care is the lack of effective tools for selecting patients posing a high risk of mortality at an early stage. Previous studies have explored risk factors associated with severity levels of the pneumonia. For example, Zhou et.al 2 identified that the older age and a high level of D-dimer are associated with in-hospital death, while Shi et.al 3 found that the manifestation of chest CT imaging abnormalities correlates with disease states. However, the\n\n\n\nFile number: 263 index pair: (6651, 6660)\nlative incidence function) of severity onset continues to increase immediately after hospital admission, but arrives its change point at day 10 ( Figure 2 ). In contrast, the cumulative incidence of the competing risks event, that is, being discharged because of recovery, is much smaller during the high risk period of severity onset. However, such incidence dramatically increases from around day 12 to 29. To personalize the time-dependent risk assessment of severe progression, we incorporated CT image data with baseline information for the risk modeling ( Figure 3) . A total of 348 quantitative feature\n\n\n\nFile number: 265 index pair: (15702, 15713)\nthe SARS-CoV outbreak in 2003, with R0 approximately at 3.0. 17 Clinical characteristic analysis shows a significantly increased age as well as elevated numbers of underlying comorbidities in severe patients than those in non-severe patients, indicating that the age and comorbidity may be important risk factors for poor outcome. Contradictory to the previous report showing a higher incidence of COVID-19 in male patients, 5 recent data including ours, consistently showed a similar proportion of male and female patients with COVID-19. 11 The patients with COVID-19 also demonstrated a decreased lymphatic co\n\n\n\nFile number: 333 index pair: (3012, 3024)\nof an older population age structure for higher fatalities and critical cases. Going forward, demographically informed projections will better predict the COVID-19 burden and inform governments about targeted action. While population age structure is crucial for understanding the populations at the highest risk of mortality both across and within countries, it is also vital for understanding how much social distancing measures are required in each population to reduce the number of most critical cases and overload on the health system-aka \"flattening the curve\"(13). Our illustrations show that countries w\n\n\n\nFile number: 333 index pair: (6133, 6144)\nca (despite extensive trade and travel links with China), suggests that the young age structure of the continent may be protective of severe and thus detectable cases, or it may be undetected. Beyond age structure, there are large sex differences in mortality that need to be understood -with men at higher risk -some of which may be accounted for by the stark differences in smoking rates by sex in Asia. Distributions of underlying comorbidities such as diabetes, hypertension and COPD will likewise refine risk estimates. Until these more nuanced data are available, the concentration of mortality risk in th\n\n\n\nFile number: 333 index pair: (15839, 15851)\nr/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . This stylized example may serve, once more, to show why while population age structure is crucial for understanding the populations at the highest risk of mortality both across and within countries, it is also important for understanding how much social distancing measures are required in each population to reduce the number of most critical cases and overload on the health system-aka \"flattening the curve.\" 6 At this time of severe crisis, policy\n\n\n\nFile number: 340 index pair: (3050, 3059)\nn binding with ACE2. However, all proteins mentioned above are engineered in laboratory by recombinant expression system, not from real virus and the structure as whole of virion is thus still lacking. Furthermore, safety is one of the major factors that restricts virus study of SARS-CoV-2 due to a high risk of possible transmission, live viruses must be operated in Biosafety A 62-year-old male was admitted to our hospital on 15 January, 2020 with pneumonia, and was further diagnosed as COVID-19. An epidemiological investigation also confirmed a Wuhan travel history between 1 January and 14 January of \n\n\n\nFile number: 346 index pair: (1073, 1084)\n comorbidities. However, there was no cross-tabulation of factors, and so it is not clear how many patients in each age group had each comorbdity, nor how the risks associated with those co-morbidities interact with each other 3 . There is one small series of 18 patients with cancer, which suggests higher risks of intubation or death, but it is so small it difficult to draw robust conclusions, and the authors' conclusions have been criticised 4 . One other study suggests patients with a history of cancer have a higher risk of becoming infected with COVID. The data from CDC China have been used to simulat\n\n\n\nFile number: 346 index pair: (1290, 1301)\nach other 3 . There is one small series of 18 patients with cancer, which suggests higher risks of intubation or death, but it is so small it difficult to draw robust conclusions, and the authors' conclusions have been criticised 4 . One other study suggests patients with a history of cancer have a higher risk of becoming infected with COVID. The data from CDC China have been used to simulate a population and then develop a risk model based on that simulated population 5 ; Although a useful step, it almost certainly leads to \"double counting\" of risk (i.e. the increased risk of death in older patients an\n\n\n\nFile number: 346 index pair: (2787, 2798)\ns who have recently received chemotherapy may be at increased risk of death from influenza infection. There are no good models to estimate the risk of death in patients who have chemotherapy and acquire COVID infection, but there are parameters from previous viral pandemics, all of which point to a higher risk of death in patients with cancer or those who are immunosupressed. Medical practice does not always require precise estimates of risk. If a decision is binary (i.e. treat/ don't treat) then what we require is an estimate of risk that is good enough to make a decision, rather than being precise.The \n\n\n\nFile number: 346 index pair: (6596, 6607)\nthe risk of infection in patients is the same as the expected population-level infection rate, population level infection may take many months to occur. A more time limited horizon is given by estimating the number of cases of time, and integrating that number. It is clear that age is a significant risk factor for death in patients infected with COVID-19. In both this and previous viral pandemics, other comorbdities have been additional risk factors. There is reasonable evidence to suggest that patients who have cancer are probably at higher risk of death, and it seems unlikely to administration of chemo\n\n\n\nFile number: 346 index pair: (6737, 6848)\ns to occur. A more time limited horizon is given by estimating the number of cases of time, and integrating that number. It is clear that age is a significant risk factor for death in patients infected with COVID-19. In both this and previous viral pandemics, other comorbdities have been additional risk factors. There is reasonable evidence to suggest that patients who have cancer are probably at higher risk of death, and it seems unlikely to administration of chemotherapy will reduce that risk fur-. CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright\n\n\n\nFile number: 346 index pair: (7602, 7632)\nifficult, and not yet possible. Due to the epidemic nature of the disease, with exponential growth in cases, while the risks today may seem small, the predicted risks over the next few months are very much higher. There is consistent evidence to suggest that patients with a history of cancer are at higher risk of adverse outcomes when infected with COVID-19. A study of 138 patients with a baseline risk of ITU admission of 26%, 40% of those with a history of cancer required ITU admission 24 , but included only 10 patients with cancer. A review of 18 cancer patients who developed COVID-19 infection showed a higher risk of ha\n\n\n\nFile number: 346 index pair: (7915, 7926)\nf adverse outcomes when infected with COVID-19. A study of 138 patients with a baseline risk of ITU admission of 26%, 40% of those with a history of cancer required ITU admission 24 , but included only 10 patients with cancer. A review of 18 cancer patients who developed COVID-19 infection showed a higher risk of harm (defined as requiring ventilation in ITU or death) 7/18 (39%) than the general population 124/1572 (8%). 12 of these 18 were being followed up after surgery, while the 4 who had undergone chemotherapy or surgery within the last month had higher risk still 4 . There is some evidence that pat\n\n\n\nFile number: 346 index pair: (8173, 8267)\nwho developed COVID-19 infection showed a higher risk of harm (defined as requiring ventilation in ITU or death) 7/18 (39%) than the general population 124/1572 (8%). 12 of these 18 were being followed up after surgery, while the 4 who had undergone chemotherapy or surgery within the last month had higher risk still 4 . There is some evidence that patients with cancer might be at higher risk of infection 25 . . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . It is worth noting that the risks associated w\n\n\n\nFile number: 371 index pair: (5137, 5148)\n in Shenyang (unpublished) ( Figure 1A ); MTB infection rates were considerably higher among COVID-19 patients than among bacterial pneumonia patients (36.11% vs 20%; p = 0.047 Figure 1A ) and viral pneumonia patients (36.11% vs 16.13%; p = 0.024), suggesting that MTB infection status is a specific risk factor for SARS-COV-2 infection rather than for pneumonia in general. The rate of MTB infection in the bacterial and other viral pneumonia . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The\n\n\n\nFile number: 371 index pair: (9222, 9233)\nfurther validation. Based on our findings, we make the following recommendations for the management and treatment of patients with a history of MTB infection (LTBI or active TB) and possible SARS-CoV-2 coinfection. First, the medical and wider community should be informed that latent/active TB is a risk factor for SARS-CoV-2 infection, and those at risk should be encouraged to pay special attention to preventive measures. Ideally, this vulnerable group should be monitored regularly at community-based medical centers in situations when resources are available. Second, the MTB infection status (history and\n\n\n\nFile number: 429 index pair: (1563, 1575)\nconfirmed cases in China up to 20 February 2020 have mild-tomoderate disease -including both non-pneumonia and pneumonia cases; whilst 13.8% developed severe disease and 6.1% developed to a critical stage requiring intensive care 8 . In a study of clinical progression in 1,099 patients 4 , those at highest risk for severe disease and death included people over the age of 60 years and those with underlying conditions (including hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer). Assessing the severity of COVID-19 is critical to determine both the appropriateness of miti\n\n\n\nFile number: 435 index pair: (8064, 8075)\nxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . https://doi.org/10.1101/2020.03.02.20029306 doi: medRxiv preprint According to the results of the binomial logistics regression analysis, we found that age and the level 157 of the D-dimer were independent risk factors. These results suggested that the level of D-dimer was 158 significantly positively correlated with the 2019-nCoV severe pneumonia, which was also shown in 159 another study [13] . Previous studies showed that SARS-CoV could bind to ACE2, down-regulating the 160 expressions of ACE2, and resulting \n\n\n\nFile number: 438 index pair: (12222, 12233)\ncount before their deaths. 6 In the study, the data of 61 patients with 2019-nCoV pneumonia were analyzed, the baseline characteristics of patients in the mild and severe groups were described and compared, and the dynamic changes of laboratory indexes and imaging were demonstrated. The independent risk factors affecting incidence of severe illness were screened. The results showed that NLR was the most significant factor affecting the severe illness incidence, and it had significant predictive value. Furthermore, according to the NLR and age stratification, the incidence of severe ill ones with NLR  3.\n\n\n\nFile number: 438 index pair: (14299, 14308)\ntients with age < 50 years old and NLR  3.13 who are low risk need to be general isolation ward. Patients with age  50 and NLR < 3.13 patients who are moderate risk, should be admitted to isolation ward with respiratory monitoring and supportive care. Patients with age  50 and NLR  3.13 who are high risk should actively transfer to ICU with invasive respiratory support equipment ( Figure 3D ). If there are large-scale cases, the risk stratification and management will help alleviate the shortage of medical resources and reduce the mortality of critical patients. There were some limitations in the s\n\n\n\nFile number: 439 index pair: (646, 657)\nth COVID-19, some special population should be paid special attention to. Epidemiological survey shows that COVID-19 patients with underlined conditions such as diabetes, hypertension, cardiovascular disease or the elderly are not only susceptible, but also often more serious. These patients are at higher risk of admission to intensive care or death [6, 7] . In addition, the profound impact inflicted by COVID-19 on pregnant women and newborns has also been noticed [8, 9] . However, as far as we know, the impact of COVID-19 epidemic on chronic kidney disease patients, especially uremic HD patients has not\n\n\n\nFile number: 441 index pair: (9026, 9035)\nion. Lymphocytopenia occurred in more than 90% of critically ill patients, which was similar in Wuhan cohort (6) . Moreover, we found that intubated patients had significantly lower lymphocyte counts than without intubation. Chi-square test had shown lower lymphocyte counts was more likely to be at high risk for intubation. Spearman correlation analyses showed that lymphocyte count was significantly negatively correlated with SOFA score at ICU admission. In fact, lymphocytopenia was common in viral pneumonia, particular in severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (M\n\n\n\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"print(\"Total number of possible text passages about risk factors: {}\".format(overall_processed_indices_count))","execution_count":142,"outputs":[{"output_type":"stream","text":"Total number of possible text passages about risk factors: 4830\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"Another problem is, even if a paper at least contains the word \"coronavirus\" doesn't mean it is about it.\nFor example one paper only lists coronavirus as a coinfection, hence the risk factors in it are not about the coronavirus but are detected as potential risk factors by this pattern matching approach."},{"metadata":{"trusted":true},"cell_type":"code","source":"#print_title(8238)","execution_count":143,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"#print_body_text(8238)","execution_count":144,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"","execution_count":null,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"","execution_count":null,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"","execution_count":null,"outputs":[]}],"metadata":{"kernelspec":{"display_name":"Python 3","language":"python","name":"python3"},"language_info":{"codemirror_mode":{"name":"ipython","version":3},"file_extension":".py","mimetype":"text/x-python","name":"python","nbconvert_exporter":"python","pygments_lexer":"ipython3","version":"3.6.10"},"pycharm":{"stem_cell":{"cell_type":"raw","metadata":{"collapsed":false},"source":[]}}},"nbformat":4,"nbformat_minor":4}